Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The Alathur facility specializes in the production of Cephalosporin antibiotics
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Subscribe To Our Newsletter & Stay Updated